Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan-Reference-Cited by-同舟云学术

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan

Published:2018-06-25 Issue:8 Volume:48 Page:771-776
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Matsumoto Ryuji¹,Abe Takashige¹,Ishizaki Junji²,Kikuchi Hiroshi¹,Harabayashi Toru²,Minami Keita²,Sazawa Ataru²,Mochizuki Tango²,Akino Tomoshige²,Murakumo Masashi²,Osawa Takahiro¹,Maruyama Satoru¹,Murai Sachiyo¹,Shinohara Nobuo¹

Affiliation:

1. Department of Urology, Hokkaido University Graduate School of Medicine

2. Hokkaido Urothelial Cancer Research Group, Sapporo, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/48/8/771/25536379/hyy094.pdf

Reference23 articles.

1. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy;Shinohara;Cancer Chemother Pharmacol,2006

2. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group;Kitamura;Cancer Sci,2011

3. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy;Kobayashi;Jpn J Clin Oncol,2016

4. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

5. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens;Bellmunt;J Clin Oncol,2010

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic models for patients with metastatic urothelial carcinoma: why use them?;Minerva Urology and Nephrology;2023-08

2. A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma;Clinical Genitourinary Cancer;2023-06

3. Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma;Cancer Medicine;2022-09-02

4. Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence;Cancers;2021-11-03

5. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR;Cancer Immunology, Immunotherapy;2021-07-07